Skip to main
NEO

NeoGenomics (NEO) Stock Forecast & Price Target

NeoGenomics (NEO) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

NeoGenomics is well positioned to maintain steady ~MSD% growth through its base clinical services business, driven by a rapidly growing NGS segment and new test launches. The company also has potential drivers for margin improvement and favorable outcomes from patent litigation, posing upside potential for investors. Additionally, NEO's relationships with community hospitals and expansion of its test menu make it an attractive player in the cancer testing space.

Bears say

NeoGenomics is expected to see slower revenue growth of 7% or less due to smaller than expected market share gains, slower test menu expansion, and potential pricing cuts to Medicare-reimbursed tests. Additionally, competition in NGS and informatics could limit growth in their legacy testing modalities. These factors contribute to the negative outlook on the stock, with a bear case scenario suggesting a potential price target of $7.00 based on an EV/sales multiple of 1.5x their estimated 2026 sales and a base case 12-month price target of $14.00 based on an EV/sales multiple of 2.5x their estimated 2026 sales.

NeoGenomics (NEO) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeoGenomics (NEO) Forecast

Analysts have given NeoGenomics (NEO) a Buy based on their latest research and market trends.

According to 7 analysts, NeoGenomics (NEO) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeoGenomics (NEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.